Aardvark Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-01-23. It has amended it 1 time. It filed its final prospectus on 2025-02-13, at a public offering price of $16.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock has been approved for listing on the Nasdaq Global Select Market (Nasdaq) under the symbol AARD.From the 424B4 filed 2025-02-13
Offering price
The initial public offering price is $16.00 per share.From the 424B4 filed 2025-02-13
Use of proceeds
We currently intend to use the net proceeds to us from this offering, together with our existing cash, cash equivalents and short-term investments, to advance the clinical development of ARD-101, to advance the clinical development of ARD-201, to fund expenses associated with our other clinical and preclinical programs and other research and development activities, and for working capital, operating expenses, capital expenditures and other general corporate purposes.From the 424B4 filed 2025-02-13
Net loss or income
For the years ended December 31, 2022 and 2023, we reported a net loss of $13.6 million and $7.2 million, respectively, and for the nine months ended September 30, 2023 and 2024, we reported a net loss of $5.2 millionFrom the S-1/A filed 2025-02-06
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-01-23 | Registration statement filed | S-1 |
| 2025-02-06 | Registration statement amended | S-1/A |
| 2025-02-13 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Aardvark Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.